Rentox (officially Re N Tox) is a 99.97% purity Korean Botox by PharmaResearch Bio, available in 100U and 200U. Clinics ordering Rentox wholesale get low-diffusion 3D contouring technology, a specific potency of 227 U/ng, and direct cold-chain export from the Gangneung GMP facility.
PharmaResearch Bio is not only a toxin manufacturer — it is the parent company behind Rejuran (PDRN/PN), giving Rentox a regenerative medicine pedigree unique among Korean Botox brands. The Gangneung GMP facility, now expanded to a projected 6 million vial annual capacity, supports consistent large-order fulfillment with the production scale required for distributor-level supply.
For clinics building a long-term Botox wholesale procurement program, Rentox offers what no other Korean toxin delivers simultaneously: a stabilized 927 kDa complex with 99.97% purity (identical specific potency to Xeomin at 227 U/ng), a low-diffusion 3D contouring profile, and a cost structure that outperforms Western incumbents without sacrificing potency or predictability.
Two new patents (Nov 2024) isolate the 150 kDa pure neurotoxin at the same specific potency as Xeomin (227 U/ng). Protein load of 0.44 ng per 100U — the same as Xeomin — means lower antigenic exposure and reduced long-term immunogenicity risk for repeat patients.
100U covers standard aesthetic scheduling for routine facial protocols. 200U suits high-volume practices treating masseter, platysmal bands, or therapeutic indications. Both vial sizes mix freely within a single Rentox bulk order, priced by total vial count.
2-8°C maintained throughout export via temperature-controlled insulated packaging. The Gangneung facility's 6 million vial annual capacity supports consistent reorder cycles for clinic and distributor accounts.
United States, Canada, United Kingdom, Germany, Poland, France, Italy, Spain, Albania, UAE (Dubai), Saudi Arabia, Qatar, Kuwait, Turkey, Brazil, Colombia, Argentina, Mexico, Thailand, Japan, Australia.
For clinics already stocking Rentox, we provide a direct restocking channel. For first-time buyers building a Rentox bulk order, we help match variant mix, volume, and route before quoting.
Rentox procurement is handled as a quote-led B2B export workflow — not a public cart checkout.
Clinic specifies Rentox 100U, 200U, or a mixed order; destination country; and target monthly volume.
We verify cold-chain stock, variant availability, and export feasibility before commitment.
Proforma invoice issued with unit sizes, quantity, and per-unit pricing.
Confirmed order moves to cold-chain packing and dispatch preparation.
Shipped via FedEx, EMS, air freight, or container; temperature maintained at 2-8°C with insulated packaging throughout transit.
Tracking shared post-dispatch; reorder planning begins after delivery confirms usage rate and remaining inventory.
Rentox is available in two vial sizes sharing identical molecular architecture. Both use the Hall Strain (ATCC 3502) and the same 927 kDa complex. The distinction lies in volume per vial and the clinical scenarios each best supports.
| Variant | Best for | Depth / Area | Needle | Lidocaine | Procurement note |
|---|---|---|---|---|---|
| Rentox 100 Units | Standard aesthetic facial sessions, clinic scheduling flexibility | Glabellar, crow's feet, forehead, neck bands | 30G | N/A | Entry point for first Rentox wholesale orders; adapts to all dilution protocols |
| Rentox 200 Units | High-volume practices, masseteric contouring, therapeutic indications | Jaw, platysmal bands, hyperhidrosis zones | 30G/27G | N/A | Per-unit cost advantage for clinics running back-to-back sessions |
Specs: Hall Strain (ATCC 3502) · 927 kDa complex · 99.97% purity · 0.44 ng protein/100U · 30G needle
Rentox 100 Units covers routine glabellar, crow's feet, and forehead treatments in a single session. The standard dilution (2.5 mL saline) yields 4.0 U per 0.1 mL — compatible with all common aesthetic dosing protocols.
Specs: Hall Strain (ATCC 3502) · 927 kDa complex · 99.97% purity · 0.44 ng protein/100U · 30G needle
Rentox 200 Units suits high-volume clinic days and large-muscle indications such as masseteric V-line contouring, hyperhidrosis, or platysmal band treatment. Per-unit cost advantage is significant when running back-to-back patient sessions.
The clinical overview PDF provides manufacturer application data, molecular specifications, and product standards for clinic buyers evaluating Rentox for wholesale procurement.
Manufacturer clinical data, molecular specifications, and application guidance for Rentox 100U and 200U.
View Clinical PDFThree field-level checks help clinics confirm Rentox vial integrity on arrival. Apply these before any reconstitution.
Verify holographic integrity of the carton seal before use. Any damage or "VOID" exposure visible on the seal is a rejection trigger — do not use a vial from a compromised carton.
Cross-check the lot number and expiry date printed on the outer carton against the individual vial label. Any discrepancy between the two indicates a non-original product.
When reconstituting, confirm that saline is drawn into the vial by visible vacuum pull. Absence of vacuum indicates a compromised seal; discard the vial and do not proceed with injection.
Rentox (officially Re N Tox) is a Botulinum Toxin Type A injectable developed by PharmaResearch Bio, the aesthetic division of PharmaResearch — the South Korean company that also manufactures Rejuran (polynucleotide/PDRN skin boosters). This regenerative medicine heritage informs the brand's approach to purity and formulation precision.
The Gangneung Science Park GMP facility commenced operations in 2019 under ISO Class 5-8 cleanroom conditions. PharmaResearch Bio pursued a global-first export strategy, shipping to Japan and Southeast Asia via export-only permits before receiving domestic MFDS approval in February 2024 — a Phase 3 BCD200 trial showed an 86.89% improvement rate. Thailand TFDA approval followed in August 2025, establishing Rentox as the ASEAN bridgehead for Vietnam, Indonesia, and Malaysia (600M+ population catchment).
The facility expansion targets 7,905 m² of production space with a projected annual capacity of 6 million vials. Cold shock fermentation at 15-25°C (rather than the standard 35°C) reduces methionine oxidation to below 1-2%, preserving SV2C receptor binding affinity and contributing to the high specific potency measured in finished product testing.
Rentox works through a four-step neuromuscular blockade pathway. Understanding the mechanism supports appropriate zone selection, dilution, and dosing for each indication.
Rentox's low-diffusion 3D Effect technology keeps the toxin concentrated at the injection site. This enables independent contouring of masseter, corrugator, and orbicularis muscles without spreading to adjacent groups. Onset: 3-5 days. Peak effect: approximately 2 weeks. Duration: 4-8 months depending on site, dose, and patient metabolism.
| Component | Amount (100U vial) | Function |
|---|---|---|
| Botulinum Toxin Type A (Hall Strain) | 100 Units / 927 kDa complex | Active neuromuscular blocking agent |
| Human Serum Albumin | 0.5 mg | Stabilizer — prevents toxin adhesion to glass surfaces |
| Sodium Chloride | 0.9 mg | Isotonic agent — reduces injection discomfort |
| Saline Added (100U vial) | Concentration | Units per 0.1 mL | Typical Use |
|---|---|---|---|
| 1.0 mL | 10 U / 0.1 mL | 10 U | High-concentration therapeutic dosing |
| 2.5 mL | 4.0 U / 0.1 mL | 4 U | Standard glabellar and aesthetic protocol |
| 4.0 mL | 2.5 U / 0.1 mL | 2.5 U | Lower-concentration superficial work |
| 5.0 mL | 2.0 U / 0.1 mL | 2 U | High-volume hyperhidrosis mapping |
Reconstitute with 0.9% sterile preservative-free saline only. Do not shake — swirl gently. Discard vial if no vacuum is observed on insertion.
Rentox's low-diffusion profile makes it suited to both focused aesthetic corrections and larger therapeutic muscle groups. The 3D Effect supports independent treatment of adjacent muscles without cross-diffusion risk.
Rentox occupies a unique position in the global toxin market: it delivers the diffusion profile of a stabilized complex (like Botox) with the purity level of a naked neurotoxin (like Xeomin) — at a Korean export price point. The two November 2024 patents specifically cover the process for isolating the 150 kDa pure neurotoxin at 99.97% purity, making Rentox the only product combining a full complex with near-naked-toxin purity metrics.
Lower protein load (0.44 ng/100U) means each treatment session exposes patients to fewer antigenic proteins than Botox (0.73 ng). Over repeated cycles, this reduces cumulative immunogenic exposure and the probability of neutralizing antibody formation — a clinically significant advantage for long-term patients.
| Product | Manufacturer | Molecular Complex | Protein Load | Specific Potency |
|---|---|---|---|---|
| Rentox | PharmaResearch Bio (KR) | 927 kDa | 0.44 ng/100U | 227 U/ng |
| Botox | Allergan (USA) | 900 kDa | 0.73 ng/100U | 137 U/ng |
| Xeomin | Merz (DE) | 150 kDa | 0.44 ng/100U | 227 U/ng |
| Dysport | Ipsen (UK/FR) | Variable | 0.65 ng/100U | 154 U/ng |
Rentox's low-diffusion technology produces controlled, precise improvements in targeted zones. The following examples show glabellar and crow's feet outcomes consistent with the 3D Effect principle of concentrated on-site muscle relaxation without adjacent spread.
Correct storage and pre-injection protocol adherence preserve product integrity from receipt through use.
Contact via WhatsApp with your required unit sizes (100U, 200U, or mixed), destination country, and estimated monthly volume. Pricing is structured by total order volume and export destination.
Yes. Mixed 100U and 200U orders are standard. Both can be combined in a single Rentox bulk order, priced by total vial count.
Rentox must be stored at 2-8°C. We use insulated temperature-controlled packaging for all air freight shipments. FedEx International Priority and EMS are primary carriers; container options are available for distributor-volume orders.
As a lyophilized powder, Rentox has a shelf life of 36 months (3 years) from manufacture. Once reconstituted with 0.9% sterile preservative-free saline, it must be used within 24 hours and kept at 2-8°C. Do not freeze.
PharmaResearch Bio's patented purification process (two new patents, Nov 2024) removes nearly all non-essential clostridial proteins and hemagglutinins. This reduces the protein load per 100U to 0.44 ng — the same as Xeomin — and significantly lowers the risk of patients developing neutralizing antibodies over repeated treatments. The 99.97% purity is achieved through proprietary acid precipitation and high-performance chromatography.
Yes — Rentox, Re N Tox, and Rientox are all the same product. Re N Tox is the official registered brand name by PharmaResearch Bio; "Rentox" is the most widely used market shorthand, and "Rientox" is a regional search variant. All three refer to the same Korean Botulinum Toxin Type A in 100U and 200U formats.
Both Rentox variants use identical molecular architecture and purity standards. The 100U vial suits clinics running standard single-session aesthetic protocols. The 200U vial provides a per-unit cost advantage for high-volume practices treating multiple patients per session, large muscle groups (masseter), or therapeutic indications that require higher total dosage.
The standard dilution is 2.5 mL of 0.9% preservative-free saline into a 100U vial, yielding 4.0 units per 0.1 mL. Five injection sites at 4U each gives a total of 20U for the glabellar complex (corrugator supercilii × 2 per side + procerus). A 30G needle is recommended for precision.
Rentox achieves a specific potency of 227 U/ng — equivalent to Xeomin and significantly higher than Botox (137 U/ng) or Dysport (154 U/ng). This means the same clinical effect is delivered with a lower total protein load (0.44 ng/100U vs Botox's 0.73 ng), reducing immunogenic exposure per treatment session.
The 3D Effect refers to Rentox's low-diffusion technology that keeps the toxin concentrated at the injection site without spreading to adjacent muscles. This allows practitioners to achieve multidimensional facial contouring — shaping masseter, corrugator, and orbicularis muscles independently — without the unintended muscle weakness or ptosis risk associated with higher-diffusion toxins.
Onset is typically within 3-5 days; peak effect at approximately 2 weeks. Duration ranges from 4-8 months depending on patient metabolism, injection site, and dose. The low-modification formulation with high protein integrity supports duration at the upper range compared to lower-purity alternatives.
